Cancer stem cell in breast cancer therapeutic resistance

Cancer Treatment Reviews

Volumn 69, Issue , 2018, Pages 152-163

  Bai, Xupeng ^a,b   Ni, Jie ^a,b   Beretov, Julia ^a,b   Graham, Peter ^a,b   Li, Yong ^a,b,c  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ZHENGZHOU UNIVERSITY   (China)

Author keywords

Breast cancer; Cancer stem cell; Pathway; Recurrence; Resistance

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; ANTHRAX TOXIN; BETA CATENIN; CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN C; SONIC HEDGEHOG PROTEIN; STAT3 PROTEIN; TESTIS DETERMINING FACTOR; TRANSCRIPTION FACTOR SOX2; WNT PROTEIN;

BREAST CANCER; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL LINEAGE; CELL MATURATION; CELL POPULATION; CELL RENEWAL; EPIGENETICS; EXTRACELLULAR MATRIX; GENETIC VARIABILITY; HUMAN; MOLECULAR EVOLUTION; NONHUMAN; PHENOTYPE; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; STEM CELL; SURVIVAL TIME; WNT SIGNALING; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; FEMALE; PATHOLOGY;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 85049872624     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2018.07.004     Document Type: Review

References (100)

1. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2017. CA Cancer J Clin 67 (2017), 7–30.
2. Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, V., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005), 2087–2106.
3. Phillips, T.M., McBride, W.H., Pajonk, F., The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98 (2006), 1777–1785.
4. Saha, S., Mukherjee, S., Khan, P., Kajal, K., Mazumdar, M., Manna, A., et al. Aspirin suppresses the acquisition of chemoresistance in breast cancer by disrupting an NFkappaB-IL6 signaling axis responsible for the generation of cancer stem cells. Cancer Res 76 (2016), 2000–2012.
5. Bonnet, D., Dick, J.E., Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 (1997), 730–737.
6. Clarke, M.F., Dick, J.E., Dirks, P.B., Eaves, C.J., Jamieson, C.H., Jones, D.L., et al. Cancer stem cells–perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66 (2006), 9339–9344.
7. Pece, S., Tosoni, D., Confalonieri, S., Mazzarol, G., Vecchi, M., Ronzoni, S., et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140 (2010), 62–73.
8. Magee, J.A., Piskounova, E., Morrison, S.J., Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21 (2012), 283–296.
9. Cicalese, A., Bonizzi, G., Pasi, C.E., Faretta, M., Ronzoni, S., Giulini, B., et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138 (2009), 1083–1095.
10. Godar, S., Ince, T.A., Bell, G.W., Feldser, D., Donaher, J.L., Bergh, J., et al. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 134 (2008), 62–73.
11. Lim, E., Vaillant, F., Wu, D., Forrest, N.C., Pal, B., Hart, A.H., et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15 (2009), 907–913.
12. Vaillant, F., Asselin-Labat, M.L., Shackleton, M., Forrest, N.C., Lindeman, G.J., Visvader, J.E., The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res 68 (2008), 7711–7717.
13. Chang-Claude, J., Dunning, A., Schnitzbauer, U., Galmbacher, P., Tee, L., Wjst, M., et al. The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk. Int J Cancer 103 (2003), 779–783.
14. Liu, B.Y., McDermott, S.P., Khwaja, S.S., Alexander, C.M., The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc Natl Acad Sci USA 101 (2004), 4158–4163.
15. Bai, X., Chen, Y., Hou, X., Huang, M., Jin, J., Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug Metab Rev 48 (2016), 541–567.
16. Polyak, K., Weinberg, R.A., Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9 (2009), 265–273.
17. Pandolfi, P.P., Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med 351 (2004), 2337–2338.
18. Berenjeno, I.M., Pineiro, R., Castillo, S.D., Pearce, W., McGranahan, N., Dewhurst, S.M., et al. Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling. Nat Commun, 8, 2017, 1773.
19. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., Clarke, M.F., Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100 (2003), 3983–3988.
20. Baccelli, I., Schneeweiss, A., Riethdorf, S., Stenzinger, A., Schillert, A., Vogel, V., et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31 (2013), 539–544.
21. Lin, Y., Zhong, Y., Guan, H., Zhang, X., Sun, Q., CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma. J Exp Clin Cancer Res, 31, 2012, 59.
22. Hwang-Verslues, W.W., Kuo, W.H., Chang, P.H., Pan, C.C., Wang, H.H., Tsai, S.T., et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One, 4, 2009, e8377.
23. Shao, J., Fan, W., Ma, B., Wu, Y., Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics. Mol Med Rep 14 (2016), 4991–4998.
24. Ricardo, S., Vieira, A.F., Gerhard, R., Leitao, D., Pinto, R., Cameselle-Teijeiro, J.F., et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 64 (2011), 937–946.
25. Leccia, F., Del Vecchio, L., Mariotti, E., Di Noto, R., Morel, A.P., Puisieux, A., et al. ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells. Mol Cancer 13 (2014), 213–226.
26. Chen, D., Bhat-Nakshatri, P., Goswami, C., Badve, S., Nakshatri, H., ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. Cancer Res 73 (2013), 5821–5833.
27. Cariati, M., Naderi, A., Brown, J.P., Smalley, M.J., Pinder, S.E., Caldas, C., et al. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 122 (2008), 298–304.
28. Wright, M.H., Calcagno, A.M., Salcido, C.D., Carlson, M.D., Ambudkar, S.V., Varticovski, L., Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res, 10, 2008, R10.
29. Liu, T.J., Sun, B.C., Zhao, X.L., Zhao, X.M., Sun, T., Gu, Q., et al. CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer. Oncogene 32 (2013), 544–553.
30. Sansone, P., Ceccarelli, C., Berishaj, M., Chang, Q., Rajasekhar, V.K., Perna, F., et al. Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nat Commun, 7, 2016, 10442.
31. Mukherjee, S., Manna, A., Bhattacharjee, P., Mazumdar, M., Saha, S., Chakraborty, S., et al. Non-migratory tumorigenic intrinsic cancer stem cells ensure breast cancer metastasis by generation of CXCR4(+) migrating cancer stem cells. Oncogene 35 (2016), 4937–4948.
32. Schaffner, F., Yokota, N., Carneiro-Lobo, T., Kitano, M., Schaffer, M., Anderson, G.M., et al. Endothelial protein C receptor function in murine and human breast cancer development. PLoS One, 8, 2013, e61071.
33. Vassilopoulos, A., Wang, R.H., Petrovas, C., Ambrozak, D., Koup, R., Deng, C.X., Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells. Int J Biol Sci 4 (2008), 133–142.
34. Rahal, O.M., Machado, H.L., Montales, M.T., Pabona, J.M., Heard, M.E., Nagarajan, S., et al. Dietary suppression of the mammary CD29(hi)CD24(+) epithelial subpopulation and its cytokine/chemokine transcriptional signatures modifies mammary tumor risk in MMTV-Wnt1 transgenic mice. Stem Cell Res 11 (2013), 1149–1162.
35. Lo, P.K., Kanojia, D., Liu, X., Singh, U.P., Berger, F.G., Wang, Q., et al. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFbeta signaling. Oncogene 31 (2012), 2614–2626.
36. Lv, X., Wang, Y., Song, Y., Pang, X., Li, H., Association between ALDH1+/CD133+ stem-like cells and tumor angiogenesis in invasive ductal breast carcinoma. Oncol Lett 11 (2016), 1750–1756.
37. Sun, M., Yang, C., Zheng, J., Wang, M., Chen, M., Le, D.Q.S., et al. Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense. Acta Biomater 28 (2015), 171–182.
38. Croker, A.K., Goodale, D., Chu, J., Postenka, C., Hedley, B.D., Hess, D.A., et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 13 (2009), 2236–2252.
39. Cheung, S.K., Chuang, P.K., Huang, H.W., Hwang-Verslues, W.W., Cho, C.H., Yang, W.B., et al. Stage-specific embryonic antigen-3 (SSEA-3) and beta3GalT5 are cancer specific and significant markers for breast cancer stem cells. Proc Natl Acad Sci USA 113 (2016), 960–965.
40. Meyer, M.J., Fleming, J.M., Lin, A.F., Hussnain, S.A., Ginsburg, E., Vonderhaar, B.K., CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res 70 (2010), 4624–4633.
41. Saha, S.K., Choi, H.Y., Kim, B.W., Dayem, A.A., Yang, G.M., Kim, K.S., et al. KRT19 directly interacts with beta-catenin/RAC1 complex to regulate NUMB-dependent NOTCH signaling pathway and breast cancer properties. Oncogene 36 (2017), 332–349.
42. Liang, Y.J., Wang, C.Y., Wang, I.A., Chen, Y.W., Li, L.T., Lin, C.Y., et al. Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype. Oncotarget 8:29 (2017), 47454–47473.
43. Sansone, P., Berishaj, M., Rajasekhar, V.K., Ceccarelli, C., Chang, Q., Strillacci, A., et al. Evolution of cancer stem-like cells in endocrine-resistant metastatic breast cancers is mediated by stromal microvesicles. Cancer Res 77 (2017), 1927–1941.
44. Leis, O., Eguiara, A., Lopez-Arribillaga, E., Alberdi, M.J., Hernandez-Garcia, S., Elorriaga, K., et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 31 (2012), 1354–1365.
45. Valenti, G., Quinn, H.M., Heynen, G., Lan, L., Holland, J.D., Vogel, R., et al. Cancer stem cells regulate cancer-associated fibroblasts via activation of hedgehog signaling in mammary gland tumors. Cancer Res 77 (2017), 2134–2147.
46. Choy, L., Hagenbeek, T.J., Solon, M., French, D., Finkle, D., Shelton, A., et al. Constitutive NOTCH3 signaling promotes the growth of basal breast cancers. Cancer Res 77 (2017), 1439–1452.
47. Solzak, J.P., Atale, R.V., Hancock, B.A., Sinn, A.L., Pollok, K.E., Jones, D.R., et al. Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer. NPJ Breast Cancer, 3, 2017, 17.
48. Ryoo, I.G., Choi, B.H., Kwak, M.K., Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells. Oncotarget 6 (2015), 8167–8184.
49. Diehn, M., Cho, R.W., Lobo, N.A., Kalisky, T., Dorie, M.J., Kulp, A.N., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458 (2009), 780–783.
50. Sultan, M., Vidovic, D., Paine, A.S., Huynh, T.T., Coyle, K.M., Thomas, M.L., et al. Epigenetic silencing of TAP1 in aldefluor(+) breast cancer stem cells contributes to their enhanced immune evasion. Stem Cells 36 (2018), 641–654.
51. Yu, J., Liao, X., Li, L., Lv, L., Zhi, X., Yu, J., et al. A preliminary study of the role of extracellular -5′- nucleotidase in breast cancer stem cells and epithelial-mesenchymal transition. Vitro Cell Dev Biol Anim 53 (2017), 132–140.
52. Antonioli, L., Yegutkin, G.G., Pacher, P., Blandizzi, C., Hasko, G., Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer 2 (2016), 95–109.
53. Beavis, P.A., Divisekera, U., Paget, C., Chow, M.T., John, L.B., Devaud, C., et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci USA 110 (2013), 14711–14716.
54. Bourguignon, L.Y., Wong, G., Earle, C., Krueger, K., Spevak, C.C., Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem 285 (2010), 36721–36735.
55. Ghatak, S., Misra, S., Toole, B.P., Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 277 (2002), 38013–38020.
56. Herrlich, P., Morrison, H., Sleeman, J., Orian-Rousseau, V., König, H., Weg-Remers, S., et al. CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann NY Acad Sci 910 (2000), 106–118.
57. Bourguignon, L.Y., Spevak, C.C., Wong, G., Xia, W., Gilad, E., Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 284 (2009), 26533–26546.
58. Muntimadugu, E., Kumar, R., Saladi, S., Rafeeqi, T.A., Khan, W., CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel. Colloids Surf B Biointerfaces 143 (2016), 532–546.
59. Balic, M., Lin, H., Young, L., Hawes, D., Giuliano, A., McNamara, G., et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12 (2006), 5615–5621.
60. Shipitsin, M., Campbell, L.L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 11 (2007), 259–273.
61. Liu, H., Patel, M.R., Prescher, J.A., Patsialou, A., Qian, D., Lin, J., et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci USA 107 (2010), 18115–18120.
62. Mylona, E., Giannopoulou, I., Fasomytakis, E., Nomikos, A., Magkou, C., Bakarakos, P., et al. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol 39 (2008), 1096–1102.
63. Liu, R., Wang, X., Chen, G.Y., Dalerba, P., Gurney, A., Hoey, T., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356 (2007), 217–226.
64. Ye, F., Qiu, Y., Li, L., Yang, L., Cheng, F., Zhang, H., et al. The presence of EpCAM(-)/CD49f(+) cells in breast cancer is associated with a poor clinical outcome. J Breast Cancer 18 (2015), 242–248.
65. Swaminathan, S.K., Roger, E., Toti, U., Niu, L., Ohlfest, J.R., Panyam, J., CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release 171 (2013), 280–287.
66. Shigdar, S., Qiao, L., Zhou, S.F., Xiang, D., Wang, T., Li, Y., et al. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett 330 (2013), 84–95.
67. Ginestier, C., Hur, M.H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1 (2007), 555–567.
68. Marcato, P., Dean, C.A., Pan, D., Araslanova, R., Gillis, M., Joshi, M., et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells Dev 29 (2011), 32–45.
69. Ginestier, C., Wicinski, J., Cervera, N., Monville, F., Finetti, P., Bertucci, F., et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 8 (2009), 3297–3302.
70. Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001), 50–56.
71. Huang, M., Li, Y., Zhang, H., Nan, F., Breast cancer stromal fibroblasts promote the generation of CD44+CD24- cells through SDF-1/CXCR4 interaction. J Exp Clin Cancer Res, 29, 2010, 80.
72. Luker, K.E., Lewin, S.A., Mihalko, L.A., Schmidt, B.T., Winkler, J.S., Coggins, N.L., et al. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene 31 (2012), 4750–4758.
73. Yi, T., Zhai, B., Yu, Y., Kiyotsugu, Y., Raschle, T., Etzkorn, M., et al. Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci USA 111 (2014), E2182–E2190.
74. Zhu, Y., Yu, F., Jiao, Y., Feng, J., Tang, W., Yao, H., et al. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 17 (2011), 7105–7115.
75. Cullen, M., Seaman, S., Chaudhary, A., Yang, M.Y., Hilton, M.B., Logsdon, D., et al. Host-derived tumor endothelial marker 8 promotes the growth of melanoma. Cancer Res 69 (2009), 6021–6026.
76. Shigdar, S., Lin, J., Yu, Y., Pastuovic, M., Wei, M., Duan, W., RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci 102 (2011), 991–998.
77. Wang, T., Gantier, M.P., Xiang, D., Bean, A.G., Bruce, M., Zhou, S.F., et al. EpCAM aptamer-mediated survivin silencing sensitized cancer stem cells to doxorubicin in a breast cancer model. Theranostics 5 (2015), 1456–1472.
78. Hyun, K.A., Koo, G.B., Han, H., Sohn, J., Choi, W., Kim, S., et al. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer. Oncotarget 7 (2016), 24677–24687.
79. Wang, D., Cai, C., Dong, X., Yu, Q.C., Zhang, X.O., Yang, L., et al. Identification of multipotent mammary stem cells by protein C receptor expression. Nature 517 (2015), 81–84.
80. Battula, V.L., Shi, Y., Evans, K.W., Wang, R.Y., Spaeth, E.L., Jacamo, R.O., et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 122 (2012), 2066–2078.
81. Sarkar, T.R., Battula, V.L., Werden, S.J., Vijay, G.V., Ramirez-Pena, E.Q., Taube, J.H., et al. GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene 34 (2015), 2958–2967.
82. Battula, V.L., Nguyen, K., Sun, J., Pitner, M.K., Yuan, B., Bartholomeusz, C., et al. IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells. Oncotarget 8 (2017), 36936–36949.
83. Fiaschi, M., Rozell, B., Bergstrom, A., Toftgard, R., Development of mammary tumors by conditional expression of GLI1. Cancer Res 69 (2009), 4810–4817.
84. O'Toole, S.A., Machalek, D.A., Shearer, R.F., Millar, E.K., Nair, R., Schofield, P., et al. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res 71 (2011), 4002–4014.
85. Schwab, L.P., Peacock, D.L., Majumdar, D., Ingels, J.F., Jensen, L.C., Smith, K.D., et al. Hypoxia-inducible factor 1alpha promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res, 14, 2012, R6.
86. Bazan-Peregrino, M., Sainson, R.C., Carlisle, R.C., Thoma, C., Waters, R.A., Arvanitis, C., et al. Combining virotherapy and angiotherapy for the treatment of breast cancer. Cancer Gene Ther 20 (2013), 461–468.
87. Zhang, C.C., Pavlicek, A., Zhang, Q., Lira, M.E., Painter, C.L., Yan, Z., et al. Biomarker and pharmacologic evaluation of the gamma-secretase inhibitor PF-03084014 in breast cancer models. Clin Cancer Res 18 (2012), 5008–5019.
88. Li, Y., Zhang, T., Korkaya, H., Liu, S., Lee, H.F., Newman, B., et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res 16 (2010), 2580–2590.
89. Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22 (2012), 66–79.
90. Chang, L., Graham, P.H., Hao, J., Ni, J., Bucci, J., Cozzi, P.J., et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis, 4, 2013, e875.
91. Cidado, J., Park, B.H., Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia. 17 (2012), 205–216.
92. Serra, V., Markman, B., Scaltriti, M., Eichhorn, P.J., Valero, V., Guzman, M., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68 (2008), 8022–8030.
93. Posada, I.M.D., Lectez, B., Sharma, M., Oetken-Lindholm, C., Yetukuri, L., Zhou, Y., et al. Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner. Oncotarget 8 (2017), 44550–44566.
94. Park, C.C., Zhang, H., Pallavicini, M., Gray, J.W., Baehner, F., Park, C.J., et al. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66 (2006), 1526–1535.
95. Xu, Y., Wang, J., Li, X., Liu, Y., Dai, L., Wu, X., et al. Selective inhibition of breast cancer stem cells by gold nanorods mediated plasmonic hyperthermia. Biomaterials 35 (2014), 4667–4677.
96. Miller-Kleinhenz, J., Guo, X., Qian, W., Zhou, H., Bozeman, E.N., Zhu, L., et al. Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer. Biomaterials 152 (2018), 47–62.
97. Polacheck, W.J., Charest, J.L., Kamm, R.D., Interstitial flow influences direction of tumor cell migration through competing mechanisms. Proc Natl Acad Sci USA 108 (2011), 11115–11120.
98. Gupta, P.B., Onder, T.T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R.A., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138 (2009), 645–659.
99. Zhang, L., Sun, H., Zhao, F., Lu, P., Ge, C., Li, H., et al. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. Cancer Res 72 (2012), 4276–4285.
100. Doherty, M.R., Jackson, M.W., The Critical, Clinical Role of Interferon-Beta in Regulating Cancer Stem Cell Properties in Triple-Negative Breast Cancer. DNA Cell Biol 37 (2018), 513–516.